A technology of dc and treg cells to treat lupus erythematosus

Abstract

A technology for treating lupus erythematosus by a DC (dendritic cell) and a Treg (T regulator cell ) comprises the following steps: (1), peripheral venous blood is collected from a non-disease period of a lupus erythematosus patient; (2), a mononuclear cell is obtained through separation from the blood with a density gradient separation method; (3), the mononuclear cell is cultured in a culture container for 2 h by a culture solution, then a supernatant is poured into a new culture container, an adherent cell in the original culture container is used for being differentiated into the DC, and a suspension cell in the new container is differentiated into the Treg; (4), a special antigen is added into the DC differentiating culture solution for DC functionalization treatment; (5), DC and Treg are mixed for culturing and amplification; and (6), an amplified cell is cleaned by normal saline and is subjected to intravenous drip for reinfusion treatment of the lupus erythematosus. According to the technology, a cellular immunity technology is adopted to recover a normal condition of an immune system, and furthermore, the DC and the Treg belong to human body cells and can remain in the body for a long period, so that long-term treatment effect is achieved.

Description

technical field [0001] The invention relates to the medical field, in particular to a technique for treating lupus erythematosus with DC and Treg cells. Background technique [0002] Lupus erythematosus is one of the typical autoimmune connective tissue diseases with systemic, chronic progressive recurrent attacks and remissions. The disease is more frequent in women and can invade multiple organs of the body. The development of immunology technology enables timely diagnosis and treatment of early mild and atypical cases. Therefore, except for a few severe cases or damage to important organs, some cases can be relieved spontaneously, and some cases only appear once. Sexual seizures, after several months or a short course of disease, the symptoms disappear completely. In terms of treatment, the ten-year survival rate of lupus patients has reached 85% due to the rational use of corticosteroid hormones, immunomodulators, plasma exchange therapy, and integration of traditional ...

AI Technical Summary

Problems solved by technology

[0006] 1. The treatment of comprehensive tissue and organ diseases is caused by lupus erythematosus, and their treatment can only relieve symptoms, treat the symptoms but not the root cause, and long-term treatment will form drug dependence and resistance

[0007] 2. Adrenal cortex hormones can cause dysfunction and dysfunction of the human body

[0008] 3. While immunosuppressant is being treated, it will cause the decline of human immunity, and patients are prone to other diseases

[0009] 4. At the same time, the long-term use of drugs makes the body in a sub-health state caused by drugs for a long time, and the drug and medical expenses are high

Images